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Background: Since recent studies revealed the feasibility to detect blood-based microRNAs (miRNAs, miRs) in breast
cancer (BC) patients a new field has been opened for circulating miRNAs as potential biomarkers in BC. In this pilot
study, we evaluated to our knowledge for the first time whether distinct pattern of urinary miRNAs might be also
applicable as innovative biomarkers for BC detection.
Methods: Urinary miRNA expression levels of nine BC-related miRNAs (miR-21, miR-34a, miR-125b, miR-155, miR-195,
miR-200b, miR-200c, miR-375, miR-451) from 24 untreated, primary BC patients and 24 healthy controls were quantified
by realtime-PCR. The receiver operating characteristic analyses (ROC) and logistic regression were calculated to assess
discriminatory accuracy.
Results: Significant differences were found in the expression of four BC-associated miRNAs quantified as median miRNA
expression levels. Urinary miR-155 levels were significantly higher in BC patients compared to healthy controls (1.49vs.0.25;
p < 0.001). In contrast, compared to healthy controls, BC patients exhibited significantly lower urinary expression levels of
miR-21 (2.27vs.5.07; p < 0.001), miR-125b (0.71vs.1.62; p < 0.001), and miR-451 (0.02vs.0.59 p = 0.004), respectively. The ROC
including all miRNAs as well as the group of the four significant deregulated miRNAs separated BC patients from healthy
controls with a very high (area under the receiver operating characteristic curve [AUC] = 0.932) and high accuracy
(AUC = 0.887), respectively.
Conclusions: We were able to demonstrate for the first time the feasibility to detect distinct BC-dependent urinary
miRNA profiles. The expression levels of four urinary miRNAs were specifically altered in our cohort of BC patients
compared to healthy controls. This distinct pattern offers the possibility for a specific discrimination between healthy
women and primary BC patients. This sustains the potential role of urinary miRNAs as non-invasive innovative urine-based
biomarkers for BC detection.
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Small non-coding microRNAs (miRNAs, miRs) with a
length of approximately 22 nucleotides are important
post-transcriptional regulators of numerous human genes.
MiRNAs modulate the expression of tumor suppressor
genes as well as oncogenes [1-3]. In breast cancer (BC),* Correspondence: elmar.stickeler@uniklinik-freiburg.de
1Department of Obstetrics and Gynecology, University Medical Center
Freiburg, Hugstetterstr. 55, Freiburg 79106, Germany
2German Cancer Consortium (DKTK), Heidelberg, Germany
Full list of author information is available at the end of the article
© 2015 Erbes et al.; licensee BioMed Central. T
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.emerging evidence suggests a potential role for deregu-
lated miRNAs as modulators of carcinogenesis, prolifera-
tion, apoptosis and drug-resistance, respectively [4]. Most
data exist for tumor tissue or breast cancer cell line-based
miRNA expression profiles [5,6]. However, there are nu-
merous hypotheses for a pivotal role of miRNAs in inter-
cellular communication [7,8] partially based on the
leakage of miRNAs in circulation [9] as well as by active
and passive export mechanisms, respectively [9]. Recent
studies documented the feasibility to detect stable miR-
NAs in serum and plasma. This opened the field for thesehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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for early detection but also outcome prediction [10-13].
Our extensive literature research revealed the following
nine miRNAs as actually relevant in BC, especially as po-
tential blood based biomarker in discrimination BC from
healthy controls or as predictors in therapy response
(Table 1). For example, high expression serum levels of
miR-10b, 34a and 155 were associated with primary meta-
static BC (p < 0.05) and high miR-34a levels correlated
with an advanced stage of disease (p = 0.01) [13]. Add-
itional data revealed a strong correlation between serum
miR-122 and miR-375 levels and neoadjuvant chemother-
apy response in locally advanced BC [14]. Overexpression
of miR-21 in BC tissue as well in blood based studies has
a relevant oncogenic role by promoting invasion, prolifer-
ation and metastases and poor prognosis in BC patients
[10,15,16]. Emerged studies showed up-regulated miR-
125b serum levels in BC patients as an innovative serum
biomarker for discrimination BC patients from healthy
controls and to predict chemotherapeutic resistance
[17,18]. Other studies indicated miR-155 and miR-195 as
promising diagnostic targets, while miR-155 is also dis-
cussed as a potential therapeutic target in BC [12,19-22].
The role of miR-200 family in blocking tumor angiogenesis
by inhibition epithelial-mesenchymal transition represents
a potential relevant therapeutic predictive parameter in BC
therapy [17,23]. Most interestingly, in one study higher ex-
pression levels of miR-200b and miR-200c were observed
in serum from circulating tumor cells (CTC)-positive
metastatic BC patients compared to CTC-negative patients
and promised miR-200b and miR-200c as an indicator for
CTC-status and a prognostic marker in metastatic BC [18].Table 1 Functional implications of circulating microRNAs and
miRNA signaling pathways target genes so
miR-21 apoptosis; EGFR PDCD4, PTEN, BCL-2, HER2,
FAS, TPM1
se
miR-34 a vascularization; EGFR,
β-Catenin
VEGF, MYC, BCL2, WNT, p53 se
miR-125b apoptosis; EGFR HER2, p53, BAK1 se
miR-155 Akt; apoptosis;
morphogenesis; EMT
VHL, VEGF, p53, TGF- β se
miR-195 apoptosis BCL 2, CDK6 w
b
se
miR-200b EMT ZEB1/2, E-Cadherin p
miR-200c EMT ZEB1/2, E-Cadherin p
miR-375 apoptosis 14-3-3 Protein p
miR-451 MDR MDR1, 14-3-3 Protein p
se
MiRNA specimen pre-selection for this study was based on previous investigations
to breast carcinogenesis.
↗: increased, ↘: decreased expression levels of miRNAs in comparison to healthy contro
multi-drug resistance.In regard of BC detection and discrimination from healthy
controls miR-451 in combination with miR-145 were iden-
tified as the best potential circulating biomarker [24].
So far, urine, as an easy approachable compartment
and a non-invasive source for circulating miRNAs, has
not been tested in the setting of BC while current stud-
ies suggest a high potential of urinary miRNAs in uro-
logic cancers [10]. In this pilot study, we evaluated to
our knowledge for the first time whether circulating
urinary miRNA pattern might be applicable as potential
biomarkers for BC detection. Therefore we assessed the
expression of a distinct panel of BC associated miRNAs
(miR-21, miR-34a, miR-125b, miR-155, miR-195, miR-
200b, miR-200c, miR-375, miR-451, respectively) in fe-
male healthy controls in comparison to newly diagnosed,
so far untreated BC patients.
Methods
Cohorts and sampling
Midstream specimen of urine (MSU) were collected in a
case–control cohort of 24 untreated patients, newly di-
agnosed with primary BC in the adjuvant setting and of
24 healthy female controls at the Department of Obstet-
rics and Gynecology, University Medical Center Freiburg
during September 2011 to August 2012. Exemplarily,
serum samples of four consecutive patients and healthy
controls were collected for a comparative analysis with
corresponding urine specimen. The specimen of urine
and serum were collected from healthy women con-
firmed not to have BC and no history of other (malig-
nant) diseases or current inflammation. For all BC
patients, distant metastasis was excluded by stagingtheir characteristic features in breast cancer patients
urce characteristic BC features references
rum ↗ in primary BC, correlation to tumor
size and lymph node status
[10,15,16,25-29]
rum ↗ in metastatic BC compared to primary
BC and controls
[13,30]
rum ↗ in primary BC, prediction of
chemotherapy resistance
[17,18,31-33]





↗ in primary BC [12,19]
rum ↘ in primary BC [22]
lasma ↗ in metastatic BC; correlation to CTC status [18,36]
lasma ↗ in metastatic BC; correlation to CTC status [18,37]
lasma ↗ in metastatic BC [14,18]
lasma,
rum
↗ in primary BC [24,38,39]
elucidating functional features and interrelations of miRNA expression in regard
ls; EMT: epithelial-mesenchymal-transition; CTC: circulating tumor cells; MDR:
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The institutional ethical review board of the University
of Freiburg, approved the investigation protocol (36/12).
All patients and healthy controls involved, gave written
informed consent for participation in this study. In
Table 2 the characteristics of the study population are
summarized. All MSU specimen were centrifuged exten-
sively to eradicate contamination with any urothelial or
microbiological cell material. Supernatant was used for
subsequent analysis. Samples were stored at −80°C until
further processing.
Statistical analysis
The statistical analyses were performed by using the SPSS
software package, version 22.0 (SPSS Inc. Chicago, IL, USA)
and the open available statistical software environment R (R
Development Core Team, “R: A Language and Environment
for Statistical Computing”. R foundation for Statistical
Computing, 2013. URL http://www.R-project.org). Mann
Whitney-U test was applied to test the median urinaryTable 2 Characteristics of breast cancer (BC) patients and
healthy controls
BC patients healthy controls p value
N 24 24
























Relevant characteristics of 24 BC patients and 24 healthy controls are demonstrated.expression levels of miR-21, miR-34a, miR-125b, miR-155,
miR-195, miR-200b, miR-200c, miR-375, and miR-451, re-
spectively. Logistic regression was used to combine all
miRNAs to a score which is interpreted as a diagnostic
marker for discrimination of cases and controls. Its accur-
acy was investigated by an ROC (receiver operating char-
acteristic) curve, the area under the curve (AUC) and
accuracy measures for a suitable cut-off value.
RNA isolation
Norgen’s Urine microRNA Purification Kit (#29000,
Norgen Biotek Corporation, Thorold, ON, Canada) was
applied for isolation and purification of small RNA mol-
ecules (< 200 nt). According to the manufacturer’s proto-
col 1 ml urine per sample was lysed and RNA was
isolated and purified in a spin column procedure. Serum
samples were diluted 1:1 with water (RNAse-free, DEPC
treated) to lower protein load before parallel RNA isolation
with Norgen’s kit. Purified miRNA was finally collected in
50 μl RNA Elution buffer (Kit component) and RNA con-
centration determined densitometrically using Eppendorf
Biophotometer (Eppendorf, Hamburg, Germany). All
miRNA samples were stored at −80°C.
Reverse transcription
Generation of miRNA-cDNA was performed by Reverse
Transcription of 250 ng miRNA/sample applying Megaplex™
Primer Pools, Human Pools A v2.1 (#4401009, Applied
Biosystems®, Life Technologies™, Thermo Fischer Scientific
Inc., Schwerte, Germany) in a total reaction volume of
20 μl. cDNA probes were stored at 4°C.
Pre-amplification
Enhancement of miRNA-cDNA quantity was achieved
by application of Megaplex™ PreAmp Primers, Human
Pool A (#4399233, Applied Biosystems®). Thereto 5 μl of
miRNA-cDNA generated by Reverse Transcription were
pre-amplified in a 20 μl reaction mix according to the
manufacturer’s protocol. Following pre-amplification,
miRNA-cDNA probes were diluted in RNAse free water
(1:3, final volume 60 μl) for subsequent PCR analysis
and stored at 4°C.
Quantitative realtime-PCR
MiRNA expression levels were determined by quantita-
tive realtime-PCR applying TaqMan® MicroRNA Assays
(#4427975, Applied Biosystems®). 1 μl miRNA-cDNA
per sample was used in a total reaction volume of 10 μl
according to the manufacturer’s protocol on Mastercycler®
ep Realplex (Eppendorf AG, Hamburg, Germany). Relative
quantification of different miRNA types resulted from ΔCt
method normalized on corresponding median expression
values of housekeeping miRNAs miR-16 and miR-26b.
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PCR analysis.
Results
As an essential prior condition for reliable miRNA quanti-
fication analysis in urine, the expression levels of various
miRNA types were investigated in regard to their potential
role as solid housekeeping genes (HKG) in this clinical
study. Since robust housekeepers of tissue-based miRNA
analyses (e.g. snRNA U) had to be excluded in advance,
our preliminary qPCR-based scanning procedure could
identify miR-16 and mir-26b as potential candidates.
Among the potential HKGs within the range offered by
supplier (ABI), expression data analysis was performed ap-
plying ‘BestKeeper’, an Excel-based tool using pair-wise
correlations for the determination of stable housekeeping
genes, differentially regulated target genes and sample in-
tegrity [40]. The assays and subsequent data analysis dem-
onstrated that miR-16 and miR-26b were characterized by
stable and consistent expression values in a set of >50
urine specimen – independent of origin from BC patients
or healthy controls (BestKeeper; miR-16: p = 0.001; miR-
26b: p = 0.001). These results indicate miR-16 and miR-
26b in urine as the best internal control for normalization
in this experimental approach.
These two miRNAs were already implemented as
HKG in different contexts of miRNA expression analyses
[10,13,41,42]. In fact, Davoren and colleagues could
identify miR-16 and miR-26b as highly ranked suitable
housekeeping miRNAs with expression stability calcu-
lated from intra- and intergroup variation (NormFinder)
and also based on an estimate of pairwise variation
(geNorm) [42]. According to current methodological
standard procedure in qPCR quantification [43,44] the
geometric mean of miR-16 and miR-26b expression
served as comparative value for quantitative assessment
of relevant miRNAs in a duplicate analysis.
The complete panel of the selected nine miRNAs was
detectable in urine by our newly designed qRT-PCR
protocol. The findings were reproducible with acceptable
inter- and intra-assay variations. Intra-assay standard devi-
ation of corresponding single values in miRNA expression
level quantification remained within a range of <0.2%,
inter-assay standard deviation within a range of <0.3%
(Additional file 1: Figure S1A, B). Expression stability of
HKG miR-16 and -26b was determined for both, BC pa-
tients and healthy controls (Additional file 2: Figure S2).
The quantification of urinary expression levels of these
miRNAs revealed distinct pattern for both, healthy con-
trols and BC patients, respectively. Our data showed sig-
nificant differences in the expression of four BC
associated miRNAs determined as median ΔCt values of
the distinct miRNA specimen normalized against the
geometric mean of the two housekeepers miR-16 andmiR-26b, respectively. In detail, urinary miRNA-155 ex-
pression was significantly increased in BC patients com-
pared to healthy controls (1.49vs.0.25; p < 0.001)
(Additional file 3: Table S1; Figure 1). In contrast, com-
pared to healthy controls, BC patients exhibited signifi-
cantly lower median urinary expression levels of miR-21,
(2.27vs.5.07; p < 0.001), miR-125b (0.71vs.1.62; p < 0.001),
and miR-451 (0.02vs.0.59; p = 0.004) (Additional file 3:
Table S1; Figure 1), respectively. For the additional miR-
NAs, miR-34a, 195, 200b, 200c, respectively, urinary ex-
pression levels did not show any significant differences
between BC patients and healthy controls (Additional
file 3: Table S1; Additional file 4: Figure S3). MiR-375
demonstrated a strong tendency towards significant ex-
pression differences between BC patients group vs. con-
trols (4.56vs.9.29; p = 0.011) (Additional file 3: Table S1;
Additional file 4: Figure S3). ROC curve analyses were
performed to evaluate the diagnostic power of the se-
lected urinary miRNAs for BC detection. The combined
nine miRNAs revealed with an excellent AUC of 0.932,
an optimal sensitivity of 0.917 (95%-CI [0.812; 1.000]) as
well as specifity of 0.917 (95%-CI [0.686; 0.978]), respect-
ively, the best diagnostic accuracy in discrimination of
BC patients from healthy controls (Figure 2A). A scoring
approach employing only the four significantly altered
miRNAs (miR-21, miR-125b, miR-155 and miR-451) still
revealed a good but lower diagnostic accuracy when
compared to the nine miRNA score, with an AUC of
0.887, sensitivity of 0.833 (95%-CI[0.697; 0.997]) and
specifity of 0.875 (95%-CI [0.640; 0.957]), respectively
(Figure 2B). In contrast, the accuracy dropped signifi-
cantly, when the four latter mentioned miRNAs were
solitarily analyzed with an AUC ranging from 0.819 to
0.773 (Figure 3).
The comparative subsequent analysis of these miRNA
profiles in serum of BC patients (n = 4) and healthy con-
trols (n = 4) showed no significant differences in median
serum levels between the two groups, respectively. In
addition the intra-group comparison of urinary to serum
miRNA levels in BC patients as well as in healthy con-
trols demonstrated no interrelation between the two dif-
ferent compartments (Additional file 3: Tables S2–S4).
Interestingly, all urine samples tested were characterized
by miR-375 expression, while corresponding serum sam-
ples did not show any detectable miR-375 levels.
Discussion
There is a growing body of evidence for a role of circu-
lating miRNAs in the serum and plasma of BC patients
as a potential non-invasive biomarker. However, data re-
garding miRNAs in urine, as an extracellular fluid com-
partment, are not available for BC patients. Our pilot
study proofs to our knowledge for the first time the pos-
sibility to detect BC related miRNA levels in urine and
Figure 1 Box plots of ΔCt-values of significant urinary miRNAs in breast cancer patients compared to healthy controls. Median urinary
expression levels of miR-21 (2.27vs.5.07; p < 0.001), miR-125b (0.72vs.1.62; p < 0.001), and miR-451 (0.02vs.0.590; p = 0.004) were significantly decreased
in BC patients compared to healthy controls, respectively. Urinary miRNA-155 expression was significantly increased in BC patients compared to healthy
controls (1.49vs.0.25; p < 0.001). Median ΔCt-value and interquartile range of duplicate experiments. Thick lines: median (50% percentile); gray boxes:
25% to 75% percentile; thin lines: minimal and maximal value,0: moderate outlier. Mann Withney-U test. Quantitative realtime-PCR.
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BC. In urine of healthy controls and patients, newly di-
agnosed for BC, we analyzed a panel of nine BC associ-
ated miRNAs (miR-21, miR-34a, miR-125b, miR-155,
miR-195, miR-200b, miR-200c, miR-375, miR-451, re-
spectively). We were able to demonstrate that the ex-
pression levels of four urinary miRNAs were specifically
and significantly altered in our cohort of 24 breast can-
cer patients. Furthermore, ROC analyses demonstrated a
significant improvement of the diagnostic potential and
accuracy when the nine investigated miRNAs were com-
bined. For this miRNA panel we were able to reach a
discriminatory power of AUC= 0.932. Even scoring with
the four most altered miRNAs (miR-21, miR-125b, miR-
155, miR-451) the accuracy was high with an AUC of
0.887. Urine levels of miR-155 were significantly induced
in BC when compared to healthy controls. These findings
are in line with recently published studies, which reported
an overexpression of miR-155 in sera and tissue samples
of primary BC patients [31,33]. MiR-155 acts as a multi-
functional miRNA with important roles in several physio-
logical and pathological processes such as inflammation,immunity, cancer and cardiovascular disease, respectively,
and was already discussed as a potential blood-based bio-
marker [31,45] . Most interestingly, the high urinary levels
of miR-155 are strongly supported by previous studies
pointing out a clear clinical correlation of miR-155 expres-
sion and breast malignancies [20,21]. High serum levels of
miR-155 were described in BC patients before surgery or
chemotherapy, while both treatment options significantly
reduced levels of circulating miR-155 in serum [21]. The
functional and clinical knowledge on miR-155 clearly sum-
marizes its oncogenic role in breast cancer as reviewed by
Mattiske et al. [20].
In contrast, the other specifically regulated urinary
miRNAs (miR-21, miR-125b, miR-375 and miR-451, re-
spectively) displayed significant decreased expression
levels compared to healthy controls. These findings are
not consistent to the current literature regarding the tis-
sue and blood expression levels of these certain miR-
NAs. Overexpression of miR-21 in tissue as well as in
serum has been correlated to advanced tumor stage,
lymph node metastasis and poor prognosis in BC pa-
tients [10,16,28,46,47]. It targets the tumor suppressor
Figure 2 ROC (receiver operating characteristic) curve of combined miRNA analysis. (A) ROC curve of all miRNAs for the score combined
from all miRNA (miR-21, miR-34a, miR-125b, miR-155, miR-195, miR-200b, miR-200c, miR-375, miR-451) in discrimination between BC patients and
healthy controls. A combined ROC (receiver operating characteristic) curve of all miRNAs showed the excellent AUC (area under the curve) of
0.932 and an optimal sensitivity of 0.917 (95%-CI [0.812; 1.000]) and specifity of 0.917 (95%-CI [0.686; 0.978]), respectively. (B) ROC curve of the four
significantly deregulated miRNAs ( miR-21, miR-125b, miR-155, miR-451) was performed and showed high diagnostic accuracy with an AUC of
0.887 and a sensitivity of 0.833 ( 95%-CI [0.697; 0.997]) and specifity of 0.875 (95%-CI [0.640; 0.957]), respectively.
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Programmed Cell Death 4 (PDCD4), thereby exhibiting
oncogenic activity by promoting tumor cell proliferation
and inhibition of apoptosis [25,29]. The differentially
expressed miR-125b was found to be up-regulated in sera
of BC patients and to have predictive power for chemo-
therapeutic resistance [31,33], which might be due to a
direct interaction of this miRNA with the tumor suppres-
sor p53 and the pro-apoptotic Bcl-2 antagonist killer1
(Bak1) [33]. Emerging evidence suggests miR-375 as a
diagnostic as well as a prognostic marker for metastatic
breast cancer. High plasma expression levels of miR-375
were found to be a sensitive marker for minimal residual
disease with circulating tumor cells and specifically dis-
criminate between metastatic BC patients and healthy
controls [18,48]. An additional trial identified high serum
levels of miR-375 in combination with miR-122 as posi-
tive predictive markers for the response to neoadjuvant
chemotherapy in locally advanced BC patients [14].
Induced levels of miR-451 together with miR-145 dis-
played also potential impact as a diagnostic biomarkers
in BC [24]. MiR-451 participates in activation of MDR1/
P-glycoprotein expression with an up-regulation in mul-
tidrug resistant cancer cell lines [49].
The observed decreased urine levels of the latter miR-
NAs do not necessarily reflect a contradiction to the
known induction in serum and tumor tissues. First, the
specimens were derived from complete separated com-
partments with unknown underlying regulatory mecha-
nisms. Weber et al. showed striking differences of miRNA
expression profiles in different human body fluids withinan individual, with the lowest variety of miRNA types de-
tectable in urine [50]. The same study demonstrated alter-
ations in miRNA expression profiles that relate to changes
in physiological and/or pathological conditions. Most
interestingly, some miRNAs showed higher expression
levels in urine compared to serum, hence implicating par-
ticular miRNA secretion processes in kidney and/or
urothelial compartments [50]. The experimental setup in
this study does not distinguish free urinary miRNA mole-
cules from miRNA particles packed in and protected by
vesicles (exosomes). However, Cheng et al. could show re-
cently, that Norgen isolation kit offers the highest yield of
exosomal miRNAs from urine samples among all com-
mercial suppliers tested [51] . Especially the occurrence of
high levels of RNase in the urinary tract, which lead to the
total degradation of free RNA types, supports our hypoth-
esis that only exosomal miRNAs remain detectable in
urine as the investigated compartment in our study
[51-53]. The results of miR-375 might serve in this con-
text as a good example. Notably, our subsequent analysis
of matched pairs of serum and urine specimen revealed a
discrepancy in miR-375 expression. Clear urinary expres-
sion was found in both groups, in contrast this miRNA
type was not detectable in serum of both, BC patients
and controls. The favorable explanation might be, that
miR-375 is secreted most likely by cells of the urinary
tract and might therefore be not specific for breast cancer
(Additional file 3: Tables S2–S4).
The signaling properties of tumor cell-secreted
miRNA-packed exosomes on normal cells have been
demonstrated in various functional studies [54-56]. The
Figure 3 ROC curves of the diagnostic potential of the individual urinary miRNAs (miR-21, miR-34a, miR-125b, miR-155, miR-195, miR-200b,
miR-200c, miR-375, miR-451) in discrimination between BC patients and healthy controls. The AUC values ranged from 0.502 to 0.819, respectively.
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based) and cellular (BC tumor tissue based) miRNA
profiles is nearly missing [39]. Moreover, a direct correl-
ation between miRNA expression levels in the two
extracellular compartments blood and urine has yet not
been clearly demonstrated. The induced level of miR-
155 together with decreased levels of four distinct miR-
NAs and four constant miRNA levels strongly suggest a
specific phenomenon with distinct regulatory pattern
rather than a general unspecific effect.
As a matter of fact this pilot study clearly accounts for
the proof of principle for the applicability of urinarymiRNA expression profiles as a potential diagnostic tool
in BC management. This study is limited by cohort size
and the case control design. Furthermore, a wider inves-
tigatory approach on larger cohorts of independent pa-
tient population is needed to validate the applied ROC
scoring system.
Since we have a distinct and exclusive look on the
urinary miRNA profile as a diagnostic and potential
prognostic/predictive tool, the observed doubtful dis-
crepancies between the existing data for tumor and
serum profiles do not compromise the value of our
analysis.
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In conclusion, with this pilot trial we demonstrate for
the first time the feasibility to detect a BC dependent
miRNA profile in urine. We are able to proof the reli-
ability, reproducibility and robustness of our self-
developed assay in the complex compartment of urine.
The test enables us to specifically discriminate between
healthy women and patients with local breast cancer.
We could identify four significantly altered and specific-
ally regulated miRNAs (miR-21, miR-125b, miR-451 and
miR-155) in BC patients compared to healthy controls.
Our present findings show typical expression patterns in
the urine of BC patients. This sustains the potential role
of urinary miRNAs as non-invasive innovative bio-
markers in detection of BC. Since this pilot study exam-
ines only a limited number of samples extended future
studies are needed to confirm these observations.
Additional files
Additional file 1: Figure S1. Inter- and intra-assay variance in qPCR
analysis in four assays. A. Inter-assay variance of miRNA types
miR-16, −21, −26b, −34a, −125b, and −155. B. Intra-assay variance of
miRNA types miR-16, −21, −26b, −34a, −125b, and −155, showing
mean standard deviation (SD) in percentage [%] as vertical-bar diagram with
numerical values below.
Additional file 2: Figure S2. HKG expression stability in qPCR analysis.
Expression values (geometric mean) of housekeeping miRNAs miR-16 and
miR-26b in BC patients (BC) and healthy controls (C). Standard deviation
(SD) and numerical values below vertical-bar diagram.
Additional file 3: Table S1. Expression levels of urinary miRNAs of BC
patients and healthy controls. Median urinary expression levels of nine
breast cancer-related miRNAs in 24 BC patients and 24 healthy controls. Mann
Withney-U test, interquartile range in parentheses. Table S2. Comparison of
miRNA expression levels in serum of BC patients and controls. Table S3.
Comparison of miRNA expression levels in serum and in urine of BC patients.
Table S4. Comparison of miRNA expression levels in serum and in urine of
controls.
Additional file 4: Figure S3. Box plots of ΔCt-values of all nine investigated
urinary miRNAs in breast cancer patients compared to healthy controls. Median
urinary expression levels of miR-21, miR-34a, miR-125b, miR-155, miR-195,
miR-200b, miR-200c, miR-375, and miR-451. Median ΔCt-value and interquartile
range of duplicate experiments. Thick lines: median (50% percentile); gray
boxes: 25% to 75% percentile; thin lines: minimal and maximal value,0: moderate
outlier,. Mann Withney-U test. Quantitative realtime-PCR.
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